Results from an international, placebo-controlled trial,1 presented for the first time at the American Academy of Neurology (AAN) Annual Meeting in Seattle, U.S.A. demonstrate that Mirapexin® / Sifrol® (pramipexole) also improves depressive symptoms, a common, disabling non-motor symptom of Parkinson`s disease (PD), in addition to its established efficacy in treating the motor symptoms of PD.
Popularity: unranked [?]
Related posts:
- Boehringer Ingelheim’s Pramipexole (Mirapexin®/Sifrol®) Shown To Improve Depressive And Motivational Symptoms In Parkinson’s Disease
- PRODEST Study Shows Many Parkinson’s Disease (PD) Patients Continue To Experience Symptoms Despite Receiving Anti-depressant Treatment
- Depressive Symptoms Related To Menopause Eased By Omega-3s
- Multidisciplinary Expert Panel Highlights Boehringer Ingelheim´s Continuing Commitment To Research In Parkinson´s Disease
- Depression Treatment And Increased Physical Activity In African Americans May Reduce Heart Disease And Improve Quality Of Life
Comments
No Responses to “Outcome Of New Mirapexin®/ Sifrol® (pramipexole) Study Set To Change Treatment Of Depressive Symptoms In Parkinson`s Disease”